Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 11.1% – Here’s Why

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) fell 11.1% during trading on Thursday . The company traded as low as $0.26 and last traded at $0.26. 72,709,392 shares were traded during trading, a decline of 5% from the average session volume of 76,777,180 shares. The stock had previously closed at $0.29.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Thursday. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Stock Performance

The company has a market capitalization of $47.84 million, a price-to-earnings ratio of 0.00 and a beta of 2.02. The firm has a fifty day simple moving average of $0.25 and a 200 day simple moving average of $0.33. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. On average, analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.